drugset

drugset / Trial / NCT02524678

Phase 1 Study(Additional) of URC102 in Healthy Subjects

NCT02524678 ↗

Phase 1 Completed 21 enrolled JW Pharmaceutical

RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to assess the safety, tolerability, PK and PD of URC102 in healthy subjects.

Timeline

Start: 2015-08-05
Primary completion: 2015-10-07
Completion: 2016-03-28

Publications

Lee HA, Yu KS, Park SI, Yoon S, Onohara M, Ahn Y, Lee H. URC102, a potent and selective inhibitor of hURAT1, reduced serum uric acid in healthy volunteers. Rheumatology (Oxford). 2019 Nov 1;58(11):1976-1984. doi: 10.1093/rheumatology/kez140.

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	URC102	Unknown	—	Oral

Indications

No indication recorded.